Abstract | BACKGROUND: METHODS: Eligible patients had advanced pancreatic adenocarcinoma that was metastatic or not amenable to resection, a Karnofsky performance status ≥70%, and no prior therapy for advanced disease. Patients received ixabepilone 32 mg/m(2) (3-hour IV infusion) every 3 weeks and cetuximab 250 mg/m(2) (1-hour IV infusion) weekly. The primary efficacy end point was the 6-month survival rate. Secondary end points included tumor response rate, overall survival, progression-free survival, and tolerability. RESULTS: A total of 54 patients were enrolled on this study. The 6-month survival rate was 57% (31/54: 95% CI: 43-71%) with a median overall survival of 7.6 months (95% CI: 5.5-12.2 months). Patients who developed acneiform rash (n = 36) had a median survival of 8.8 months, compared with 2.6 months for those without rash (n = 18). Of 31 patients with measurable disease (defined as response-evaluable), 4 had confirmed partial responses and an additional 24 had stable disease. The combination was generally well-tolerated with the most common grade 3/4 hematological toxicities being leucopenia (39%) and neutropenia (33%). The most common grade 3/4 nonhematologic toxicity was fatigue (17%). CONCLUSIONS:
|
Authors | Caio M Rocha Lima, Edward H Lin, George P Kim, Jeffrey K Giguere, John Marshall, Mark Zalupski, Chris Papageorgio, Miklos L Auber, Remigiusz Kaleta, M Brent McHenry, Ovidiu C Trifan, Philip A Philip |
Journal | Gastrointestinal cancer research : GCR
(Gastrointest Cancer Res)
Vol. 5
Issue 5
Pg. 155-60
(Sep 2012)
ISSN: 1934-7987 [Electronic] United States |
PMID | 23112883
(Publication Type: Journal Article)
|